Cargando…

Conditional survival and hazards of death for peripheral T-cell lymphomas

Typically, peripheral T-cell lymphoma (PTCLs) prognosis is estimated using overall survival before treatment. However, these estimates cannot show how prognosis evolves with the changing hazard rate over time. Patients (n = 650) with newly diagnosed PTCLs were enrolled retrospectively. After a media...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Hongye, Ji, Xinqiang, Liu, Xin, Mi, Lan, Liu, Weiping, Wang, Xiaopei, Zhu, Jun, Song, Yuqin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8064157/ https://www.ncbi.nlm.nih.gov/pubmed/33819191 http://dx.doi.org/10.18632/aging.202782

Ejemplares similares

Effect of autologous hematopoietic stem cell transplantation for patients with peripheral T-cell lymphoma in China: A propensity score-matched analysis
por: Gao, Hongye, et al.
Publicado: (2022)

Conditional Survival and Annual Hazard Estimates of Classical Hodgkin Lymphoma
por: Nuersulitan, Reyizha, et al.
Publicado: (2021)

Different situations of identifying second primary malignant tumors in lymphoma patients with synchronous solid tumors
por: Gao, Hongye, et al.
Publicado: (2023)

A Comparison of Clinical Prognostic Indices in Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with a Pegylated Liposomal Doxorubicin Combination Regimen in China
por: Gao, Hongye, et al.
Publicado: (2022)

Correlation of mutational landscape and survival outcome of peripheral T-cell lymphomas
por: Ye, Yingying, et al.
Publicado: (2021)

Effect of infection with hepatitis B virus on the survival outcome of diffuse large B-cell lymphoma in the prophylactic antiviral era
por: Nuersulitan, Reyizha, et al.
Publicado: (2022)

The Clonal Diversity of Peripheral B Cell Receptor Immune Repertoire Impaired by Residual Malignant B Cells Predicts Treatment Efficacy in B Cell Lymphoma Patients
por: Wu, Meng, et al.
Publicado: (2022)

Improving survival of 3760 patients with lymphoma: Experience of an academic center over two decades
por: Liu, Weiping, et al.
Publicado: (2020)

Burden of lymphoma in China, 2006–2016: an analysis of the Global Burden of Disease Study 2016
por: Liu, Weiping, et al.
Publicado: (2019)

Single or tandem autologous stem cell transplantation for treating Chinese patients with refractory/relapsed classical Hodgkin lymphoma
por: Zhang, Chen, et al.
Publicado: (2023)

Burden of lymphoma in China, 1990−2019: an analysis of the global burden of diseases, injuries, and risk factors study 2019
por: Liu, Weiping, et al.
Publicado: (2022)

Outcome and Prospective Factor Analysis of High-dose Therapy Combined with Autologous Peripheral Blood Stem Cell Transplantation in Patients with Peripheral T-cell Lymphomas
por: Wu, Meng, et al.
Publicado: (2018)

Mortality of lymphoma and myeloma in China, 2004–2017: an observational study
por: Liu, Weiping, et al.
Publicado: (2019)

Epidemiological Characteristics of Peripheral T-Cell Lymphoma: A Population-Based Study
por: Liu, Shuo, et al.
Publicado: (2022)

P1287: HETROMBOPAG FOR ENHANCEMENT OF PLATELET ENGRAFTMENT IN PATIENTS WITH LYMPHOMA AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Zhao, Linjun, et al.
Publicado: (2023)

Risk-Dependent Conditional Survival and Failure Hazard After Radiotherapy for Early-Stage Extranodal Natural Killer/T-Cell Lymphoma
por: Liu, Xin, et al.
Publicado: (2019)

A Prospective Phase II Study of Pegaspargase-COEP Plus Radiotherapy in Patients With Newly Diagnosed Extra-Nodal NK/T-Cell Lymphoma
por: Hu, Shaoxuan, et al.
Publicado: (2022)

EP300 single nucleotide polymorphism rs20551 correlates with prolonged overall survival in diffuse large B cell lymphoma patients treated with R-CHOP
por: Li, Jiao, et al.
Publicado: (2017)

Long-term survival benefit of anti-PD-1 therapy in patients with relapsed or refractory classical Hodgkin lymphoma
por: Liu, Weiping, et al.
Publicado: (2023)

Safety, Efficacy, Pharmacokinetic and Pharmacodynamic evaluation of YF-H-2015005 for mobilizing Hematopoietic stem cells in Non-Hodgkin's Lymphoma Patients
por: Liu, Weiping, et al.
Publicado: (2020)

Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography using Deauville criteria in diffuse large B cell lymphoma treated with autologous hematopoietic stem cell transplantation
por: Ying, Zhitao, et al.
Publicado: (2019)

A prospective phase II study of L-asparaginase- CHOP plus radiation in newly diagnosed extranodal NK/T-cell lymphoma, nasal type
por: Lin, Ningjing, et al.
Publicado: (2013)

Outcomes of dose-adjusted Berlin–Frankfurt–Münster-90 regimen without radiotherapy in adolescents and adults with T cell lymphoblastic lymphoma
por: Xie, Yan, et al.
Publicado: (2015)

The Incidence of Lymphoma in Beijing: Comparing Results from MIS-CASS (2019) and Beijing Cancer Registry (2017)
por: Tian, Hongrui, et al.
Publicado: (2021)

Mortality Rate of Lymphoma in China, 2013–2020
por: Liu, Weiping, et al.
Publicado: (2022)

Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven Chinese patients with untreated diffuse large B-cell lymphoma
por: Fu, Zhiying, et al.
Publicado: (2014)

Causes of death and conditional survival estimates of long-term lung cancer survivors
por: Zhang, Qun, et al.
Publicado: (2022)

Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin’s Lymphoma
por: Ying, Zhitao, et al.
Publicado: (2019)

PEG-asparaginase in BFM-90 regimen improves outcomes in adults with newly diagnosed lymphoblastic lymphoma
por: Zheng, Wen, et al.
Publicado: (2017)

A durable 4-1BB-based CD19 CAR-T cell for treatment of relapsed or refractory non-Hodgkin lymphoma
por: Ying, Zhitao, et al.
Publicado: (2022)

PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity
por: Zheng, Wen, et al.
Publicado: (2018)

Survival and prognostic analysis of T-cell lymphoblastic lymphoma patients treated with dose-adjusted BFM-90 regimen
por: Yu, Hui, et al.
Publicado: (2022)

Epstein-Barr virus positive peripheral T cell lymphoma with novel variants in STAT5B of a pediatric patient: a case report
por: Chen, Zihang, et al.
Publicado: (2018)

TP53 Arg72 as a favorable prognostic factor for Chinese diffuse large B-cell lymphoma patients treated with CHOP
por: Liu, Yalu, et al.
Publicado: (2017)

Treatment, Survival, and Prognosis of Advanced-Stage Natural Killer/T-Cell Lymphoma: An Analysis From the China Lymphoma Collaborative Group
por: Liu, Weiping, et al.
Publicado: (2021)

Chidamide combined with cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with peripheral T-cell lymphoma
por: Gui, Lin, et al.
Publicado: (2021)

ITK inhibition induced in vitro and in vivo anti-tumor activity through downregulating TCR signaling pathway in malignant T cell lymphoma
por: Liu, Yalu, et al.
Publicado: (2019)

Cerebrospinal Fluid Proteins Identification Facilitates the Differential Diagnosis of Central Nervous System Diffuse Large B Cell Lymphoma
por: Zheng, Wen, et al.
Publicado: (2017)

Autologous hematopoietic stem cell transplantation improves survival outcomes in peripheral T-cell lymphomas: a multicenter retrospective real-world study
por: Wu, Meng, et al.
Publicado: (2023)

PB2351: TRIAL IN PROGRESS: A PHASE 2, MULTICENTRE STUDY OF BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY IN FRONTLINE TREATMENT OF CHINESE PATIENTS WITH CD30-POSITIVE PERIPHERAL T-CELL LYMPHOMAS
por: Song, Yuqin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_osa7vao4bvu1a0clfa9n7jm00b